FindTrial
Sign In

Immunocytochemistry for hTERT, CD56 and HBME-1 in thyroid tumors

Cytological expression of hTERT, CD56, HBME-1 in thyroid neoplasms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/025597
Enrollment
20
Registered
2020-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C73- Malignant neoplasm of thyroid gland

Interventions

Control Intervention1: NIL: NIL Control Intervention2: NIL: NIL

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.New cases of thyroid masses reported as Bethesda III-VI. 2.Cases of thyroid masses reported as definitely Benign lesions (Bethesda II).

Exclusion criteria

Exclusion criteria: 1.Cases of thyroid masses who have received previous radio or chemo therapy. 2.Cases of thyroid masses who have received previous treatment for hyper- or hypothyroidism.

Design outcomes

Primary

MeasureTime frame
Cytological expressions of hTERT, CD56 and HBME-1 in thyroid lesions.Timepoint: Single Time.—

Secondary

MeasureTime frame
Based on the expression of these markers differentiating thyroid lesions into various Bethesda categories and correlating with histopathology.Timepoint: Single Time.—

Countries

India

Contacts

Public ContactAnjali Mittal

Maulana Azad Medical College

meetamamc@gmail.com9968604327

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026